🇺🇸 FDA
Patent

US 9833468

Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA

granted A61KA61K31/713A61K47/6455

Quick answer

US patent 9833468 (Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA) held by The United States of America as Represented by the Secretary, Dept. of Health and Human Services expires Mon Nov 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary, Dept. of Health and Human Services
Grant date
Tue Dec 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
51
CPC classes
A61K, A61K31/713, A61K47/6455, A61P, A61P43/00